Cyclosporine (CSA), in both humans and animals, is associated with plasma lipoproteins. It
has been demonstrated that CSA-lipoprotein association is partly responsible for the …

Hyperlipidaemia commonly develops in both transplant recipients and experimental animals
receiving cyclosporin A (CsA). However, the threshold of CsA induced-changes on …

Purpose: The objective of the study was to examine the effect of lipoprotein-associated
cyclosporine on hepatic metabolism, hepatic lipoprotein receptors, and renal toxicity in …

Purpose. The purpose of this study was to define the relationship between lipoprotein (LP)
lipid concentration and composition and the distribution of cyclosporine (CSA) in human …

Purpose. This study investigated the effects of low (LDL) and high density lipoproteins (HDL)
on renal cyclosporine A (CsA) and cyclosporine G (CsG) disposition in the isolated perfused …

The purpose of this study was to assess the effect of hyperlipoproteinemia on the
biodistribution of cyclosporine A (CyA), an extensively lipoprotein bound …

The present study attempted to characterize the distribution of cyclosporin A (CsA) among
the lipoprotein fractions, very-low-, intermediate-, low-, and high-density (VLDL, IDL, LDL …

Hyperlipidemia is an identified risk factor for atherosclerosis in patients following renal
transplantation that may be related to previous uremia and various drugs including steroids …

The present study was designed to systematically investigate sequential changes in CsA
pharmacokinetics in renal transplant recipients. Factors that may affect CsA …

Cyclosporine A (CSA) is an effective immunosuppressant, but side effects such as renal
toxicity can limit its therapeutic use. The current studies investigate the effects of lipoproteins …